MANKIND - IntraDay Trade Analysis with Live Signals
← Back to ListKey Parameters
⭐ IntraDay Trade Rating: 3.8
✅ Positive
The company reported a significant increase in profit (29.6%) and revenue growth (12.9%) during the Q1 results, indicating strong performance. Additionally, a positive change in DII holding (0.93%) suggests growing investor interest.
⚠️ Limitation
Despite the favorable earnings report, the stock’s P/E ratio is high (45.1) compared to the industry average (33.6), and the PEG ratio of 2.22 indicates overvaluation relative to growth potential. The recent price decline also introduces uncertainty.
📉 Company Negative News
Recent news highlights a 5% drop in share price despite rising profits, indicating investor concerns or anticipated corrections. The sale of Broadway Hospitality stake may be viewed negatively by some investors.
📈 Company Positive News
Mankind Pharma reported a substantial increase in profit to ₹568 crore and revenue growth of 12.9% during the Q1 results, showcasing strong business performance.
🏭 Industry
The pharmaceutical industry is currently experiencing robust demand driven by increasing healthcare awareness and rising disposable incomes, particularly in emerging markets. Competition within the sector remains intense, but key players are focusing on innovation and expanding market reach.
🧾 Conclusion
A buy price of 2,450 ₹ offers a slight undervaluation considering the recent earnings surge. An initial exit level at 2,520 ₹ targets a 5% profit gain, while a stop-loss order at 2,430 ₹ provides protection against potential downside if momentum weakens. Overall, this stock presents an opportunistic entry point due to its positive fundamentals and increasing volume.